Newsfeeds Archive - Page 9 of 9

4 minute read

BMF-219 Enters the Clinic For KRAS Solid Tumor; Biomea Fusion Announces FDA Clearance Of Investigational New Drug Application For Covalent Menin Inhibitor BMF-219 In KRAS Solid Tumors

October 14, 9:02 AM

Biomea Fusion announces FDA clearance of Investigational New Drug (IND) application for covalent menin inhibitor BMF-219 in KRAS solid tumors. Biomea Fusion will now initiate a Phase I/Ib clinical trial

BMEA

3 minute read

Recap Of Friday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan

August 26, 7:52 PM

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…

BCRX

1 minute read

Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate

By Vandana Singh

August 26, 1:13 PM

Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting.

BMEA

2 minute read

How Is The Market Feeling About Biomea Fusion?

By Benzinga Insights

August 18, 11:45 AM

BMEA

3 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s Intraday Session

By Benzinga Insights

August 17, 1:34 PM

AKU

1 minute read

Earnings

Biomea Fusion: Q2 Earnings Insights

By Benzinga Insights

August 1, 6:02 PM

Biomea Fusion (NASDAQ:BMEA) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

BMEA

1 minute read

Biomea Fusion Q2 EPS $(0.59) Down From $(0.33) YoY

By Benzinga Newsdesk

August 1, 4:19 PM

Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.59) per share. This is a 78.79 percent decrease over losses of $(0.33) per share from the same period last year.

BMEA